Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELAN Elanco Animal Health	$14.48 -1.1%	$13.03	$8.02 ▼ $15.78	$7.27B	1.67	5.08 million shs	3.21 million shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$68.98 ▼ $131.98	$14.05B	0.69	1.53 million shs	N/A
SMMT Summit Therapeutics	$22.61 -7.9%	$22.72	$7.23 ▼ $36.91	$18.23B	-1.01	3.70 million shs	4.35 million shs
TEVA Teva Pharmaceutical Industries	$16.84 -1.0%	$17.03	$12.47 ▼ $22.80	$19.51B	0.6	10.24 million shs	9.69 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELAN Elanco Animal Health	-1.09%	+1.33%	+3.84%	+74.14%	+1.83%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	0.00%	+89.58%
SMMT Summit Therapeutics	-7.13%	+6.25%	+9.81%	+35.88%	+212.29%
TEVA Teva Pharmaceutical Industries	-1.23%	+0.48%	-5.18%	+24.42%	+2.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELAN Elanco Animal Health	2.3411 of 5 stars	1.3	4.0	0.3	1.9	1.7	1.3
ITCI Intra-Cellular Therapies	0.7371 of 5 stars	1.1	0.0	4.5	0.0	1.7	0.6
SMMT Summit Therapeutics	2.4842 of 5 stars	4.4	1.0	0.0	1.9	1.7	0.0
TEVA Teva Pharmaceutical Industries	4.1875 of 5 stars	4.6	3.0	0.0	2.8	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELAN Elanco Animal Health	2.50	Moderate Buy	$15.33	5.89% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	53.32% Upside
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.13	43.26% Upside

Current Analyst Ratings Breakdown

Latest ELAN, TEVA, ITCI, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $17.00
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/26/2025	ELAN Elanco Animal Health	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELAN Elanco Animal Health	$4.44B	1.62	$2.23 per share	6.50	$12.33 per share	1.17
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.53 per share	N/A
TEVA Teva Pharmaceutical Industries	$16.54B	1.17	$3.33 per share	5.06	$4.74 per share	3.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELAN Elanco Animal Health	$338M	$0.74	19.57	16.27	2.86	8.43%	7.54%	3.57%	8/6/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.40	0.87	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest ELAN, TEVA, ITCI, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	N/A	N/A	N/A	$4.34 billion	N/A
5/7/2025	Q1 2025	ELAN Elanco Animal Health	$0.31	$0.37	+$0.06	$0.14	$1.17 billion	$1.19 billion
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELAN Elanco Animal Health	0.68	2.71	1.46
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
SMMT Summit Therapeutics	N/A	10.63	10.63
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELAN Elanco Animal Health	97.48%
ITCI Intra-Cellular Therapies	92.33%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ELAN Elanco Animal Health	0.89%
ITCI Intra-Cellular Therapies	2.60%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELAN Elanco Animal Health	9,000	496.65 million	492.23 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

ELAN, TEVA, ITCI, and SMMT Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Boosted by IFM Investors Pty Ltd

1 hour ago | marketbeat.com

Stock Traders Purchase Large Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

July 7 at 1:38 PM | marketbeat.com

Teva Pharmaceutical Industries Ltd. ADR Stock Grades - Barron's

July 7 at 5:21 AM | barrons.com

Leader Capital Markets Keeps Their Buy Rating on Teva (TEVA)

July 7 at 5:21 AM | theglobeandmail.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Buy" from Brokerages

July 7 at 2:33 AM | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Buy" from Analysts

July 7 at 2:30 AM | marketbeat.com

Teacher Retirement System of Texas Reduces Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 6 at 4:51 AM | marketbeat.com

Cambridge Investment Research Advisors Inc. Purchases 41,600 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 5 at 3:41 AM | marketbeat.com

Harel Insurance Investments & Financial Services Ltd. Buys 22,044,407 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 4, 2025 | marketbeat.com

Straight Path Wealth Management Decreases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 3, 2025 | marketbeat.com

WCM Investment Management LLC Increases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by DAVENPORT & Co LLC

July 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

July 2, 2025 | marketbeat.com

Billionaire Stanley Druckenmiller Sold Palantir And Buying This Stock Instead

July 1, 2025 | 247wallst.com

Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen solid returns of 112% over the past three years

July 1, 2025 | finance.yahoo.com

Allspring Global Investments Holdings LLC Purchases 5,186,592 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29, 2025 | marketbeat.com

Sequoia Financial Advisors LLC Increases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29, 2025 | marketbeat.com

Asset Management One Co. Ltd. Reduces Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29, 2025 | marketbeat.com

Achmea Investment Management B.V. Sells 122,509 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 28, 2025 | marketbeat.com

UBS Group Lowers Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $23.00

June 28, 2025 | americanbankingnews.com

Teva’s CEO shares ‘Pivot to Growth’ progress

June 27, 2025 | fiercepharma.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
3 Top Stocks Under $20 Riding the “Made in America” Wave
By Chris Markoch | July 3, 2025
View 3 Top Stocks Under $20 Riding the “Made in America” Wave

ELAN, TEVA, ITCI, and SMMT Company Descriptions

Elanco Animal Health NYSE:ELAN

$14.48 -0.16 (-1.09%)

As of 07/7/2025 03:59 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$22.61 -1.94 (-7.90%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$22.75 +0.14 (+0.62%)

As of 07/7/2025 07:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$16.84 -0.17 (-1.00%)

Closing price 07/7/2025 03:59 PM Eastern

Extended Trading

$16.90 +0.07 (+0.39%)

As of 07/7/2025 06:40 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time